Why the study?
Does one dose of WC3 rotavirus vaccine prevent symptomatic rotavirus diarrhea in healthy infants 2-12 months of age?
Does one dose of WC3 rotavirus vaccine prevent symptomatic rotavirus diarrhea in healthy infants 2-12 months of age?
A single dose of WC3 rotavirus vaccine was safe and immunogenic but did not significantly reduce the overall incidence of symptomatic rotavirus diarrhea in healthy infants.
Answers are grounded in this paper and cite their sources.
Single-dose WC3 rotavirus vaccine does not prevent symptomatic diarrhea in infants; challenges single-dose regimens and supports multi-dose evaluation in future trials.
The safety, immunogenicity, and efficacy of WC3 rotavirus vaccine was evaluated in a double-blind, placebo-controlled trial of healthy infants 2-12 months of age; 103 received one dose of vaccine and 103 received placebo. Vaccination appeared to be safe and induced an antibody response (WC3 neutralizing antibody) in 97% of vaccinees. Only 9 (9%) of these, however, produced antibody to human rotavirus serotypes; at least 7 of the 9 were naturally infected before vaccination. Neither the number of symptomatic episodes of rotavirus diarrhea (21 vs 25) nor the number of moderate to severe rotavirus illnesses (9 vs. 15) was significantly different in vaccine or placebo recipients, respectively, during a predominantly serotype 1 rotavirus season. A slight but significant decrease in mean symptom score was detected in vaccine recipients. Despite an overall lack of efficacy, protection could be correlated to previous rotavirus infection, high levels of WC3 neutralizing antibody, and preexisting (maternal) serotype 1 neutralizing antibody with a titer greater than or equal to 30.
No takes yet. Share an insight, caveat, or question.
Bernstein et al. (1990) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: